Tebentafusp Trial
Phase 3
540
about 5.6 years
18+
25 sites in AZ, FL, GA +15
About this study
Researchers are testing whether tebentafusp, alone or with pembrolizumab, is more effective than the treatment chosen by doctors (investigator's choice) for people with advanced melanoma that has not responded to other treatments. The trial will last about 2 years.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Investigators Choice
- 2.Take Tebentafusp
- 3.Take Tebentafusp with Pembrolizumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), tebentafusp
infusion
Primary: Overall Survival (OS)
Secondary: Change from Baseline in Circulating Tumor DNS (ctDNA), Number of participants with Grade ≥2 cytokine release syndrome (CRS), Number of participants with dose interruptions, reductions, and discontinuations from study therapy due to AEs, Number of participants with ≥1 adverse event (AE), Number of participants with ≥1 serious adverse event (SAEs), Responses to the EORTC Core Quality of Life (EORTC-QLQ-C30), Responses to the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)
Oncology